<DOC>
	<DOCNO>NCT00110617</DOCNO>
	<brief_summary>This study examine long-term safety efficacy Deferasirox patient sickle cell disease iron overload repeat blood transfusion .</brief_summary>
	<brief_title>Study Deferasirox Relative Subcutaneous Deferoxamine Sickle Cell Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Iron Overload</mesh_term>
	<mesh_term>Anemia , Hemolytic</mesh_term>
	<mesh_term>Deferasirox</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>Age great equal 2 year Male female patient sickle cell disease ( SS , SC , SD , Sβo Sβ+ thalassemia ) Iron overload repeat blood transfusion , define one following : 1 . For patient &gt; 16 year old receive simple transfusion : lifetime history receipt least 120 ml/kg 30 adult unit pack red blood cell , OR 2 . For patient ≤ 16 year old receive simple transfusion : lifetime history receipt least 120 ml/kg pack red blood cell , OR 3 . For patient receive exchange transfusion absence previous attempt achieve negative iron balance : lifetime performance least 20 procedure , OR 4 . For patient : liver iron content ≥ 7 mg Fe/g dry weight measure biopsy , Magnetic Resonance Imaging ( MRI ) , magnetic susceptibility perform within 3 month prior entry screen For entry screen period : serum ferritin ≥ 1000 µg/mL least two occasion prior year obtain absence concomitant infection . Body weight &gt; 10 kg No known allergy contraindication administration deferoxamine Ability comply studyrelated procedure , medication , evaluation Sexually active premenopausal female patient must use doublebarrier contraception , oral contraceptive plus barrier contraceptive , must undergo clinically document total hysterectomy and/or oophorectomy , tubal ligation postmenopausal define amenorrhea least 12 month . Written informed consent patient pediatric patient 's consent patient 's legal guardian . The definition term 'pediatric ' enrollment study conduct accordance local legislation . Serum creatinine upper limit normal Significant proteinuria History nephrotic syndrome Alanine aminotransferase ( ALT ) ≥ 250 U/L screen Clinical evidence active hepatitis B hepatitis C History HIV Fever signs/symptoms infection within 10 day prior screen visit Uncontrolled systemic hypertension History Myocardial Infarction , Congestive Heart Failure unstable cardiac disease control standard medical therapy Clinically relevant cataract previous history clinically relevant ocular toxicity relate iron chelation Presence surgical medical condition might significantly alter absorption , distribution , metabolism excretion study drug History drug alcohol abuse within 12 month prior enrollment Pregnant breast feeding patient Patients treated systemic investigational drug within 4 week prior topical investigational drug 7 day prior screen visit Randomization previous clinical trial involve ICL670 Other protocolrelated inclusion / exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Sickle Cell Disease</keyword>
	<keyword>Iron Overload Repeated Blood Transfusions</keyword>
	<keyword>Iron Overload</keyword>
	<keyword>Blood Transfusions</keyword>
</DOC>